HOME >> BIOLOGY >> NEWS
Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane

(Houston -- June 11, 2004) US Oncology (Nasdaq: USON) announced that data presented this week by a network physician at the American Society of Clinical Oncology annual meeting demonstrate that the investigational drug AbraxaneTM (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol) and/or docetaxel (Taxotere).

Based on analysis to date, results showed a 15 percent (95% CI: 8-22%) overall response rate in 106 patients who received Abraxane 100 mg/m2 administered weekly over 30 minutes a day without premedication for three weeks followed by one week of rest, with a 38 percent probability of surviving 12 months. Additionally, 40 percent of patients were free of disease progression for as long as four months, and almost 30 percent for as long as six months. Ninety-one percent of patients were able to receive the full dose throughout the study without dose reduction.

Joanne Blum, M.D., PhD., a US Oncology Principal Investigator at Texas Oncology PA (TOPA), who practices at Charles A. Sammons Cancer Center, Baylor University Medical Center in Dallas, Texas, presented the update. Charles A. Sammons Cancer Center was one of 38 US Oncology affiliated practices that had patients participate in the Abraxane clinical trial.

All patients in the trial, sponsored by American Bioscience, Inc., had progressive metastatic breast cancer while being treated with Taxol or Taxotere in the metastatic setting, or had a relapse within 12 months of adjuvant taxane therapy. The patient population studied had a poor prognosis with 91 percent having visceral (lung and liver) disease, 65 percent with more than three metastatic sites and 88 percent demonstrating ongoing tumor growth while on Taxol or Taxotere.

"The activity of Abraxane and the tolerance of the weekly reg
'"/>

Contact: Melyssa Weible
MWeible@healthstarpr.com
646-328-1457
HealthStar PR
14-Jun-2004


Page: 1 2

Related biology news :

1. Breastfeeding decreases infant mortality
2. Breast cancer study suggests role for tissue in carcinogenesis
3. Breast self examination increases womens concerns but has no effect on mortality
4. Breast cancer follow-ups no longer guess-work thanks to new physics research
5. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
6. The 4th European Breast Cancer Conference (EBCC4)
7. Breast cancer susceptibility genes play role in DNA repair
8. Breast cancer can be reversed in laboratory mice, scientists report
9. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
10. Breast fluid a better option for detecting cancer
11. Breastfeeding may compensate for harmful effects of smoking during pregnancy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/5/2020)... ... 2020 , ... Patients in need of new teeth after tooth extraction or ... Dental Implants of Ocala. Same-day dental implants allow patients with an entire ... one day. This treatment utilizes advanced technology and Dr. Brand’s unique experience and skills ...
(Date:3/5/2020)... (PRWEB) , ... March 05, 2020 , ... ... AlphaSTEM Test™ technology . The AlphaSTEM Test™ is the first, and ... stem cells. Other technologies that attempt to provide information about the number ...
(Date:3/4/2020)... ... 04, 2020 , ... The Massachusetts Medical Device Industry Council ... program’s 2020 IGNITE Cohort. The MedTech IGNITE Program is a virtual accelerator offering ... generation of medtech founders and entrepreneurs. IGNITE Cohort members get access to medtech, ...
Breaking Biology News(10 mins):
(Date:2/21/2020)... ... February 20, 2020 , ... ... and elegant chemistry. Humans have been increasingly successful in innovating ways to ... rapidly evolving technologies and strategies for modern molecular biology (e.g., gene sequencing, ...
(Date:2/21/2020)... ... February 21, 2020 , ... Join Forrest Brown, Engineering Services ... Sequence, Inc. for an informative session on Wednesday, February 26, ... Key elements to incorporate into facility design to add manufacturing flexibility in the future, ...
(Date:2/19/2020)... (PRWEB) , ... February 18, 2020 , ... ... tools for characterizing microbiome populations down to the strain level, recently unveiled a ... kit designed for efficient and unbiased isolation of high molecular weight (HMW) single-stranded ...
(Date:2/19/2020)... (PRWEB) , ... February 19, 2020 , ... ... process solutions for the life sciences industry, today announced the opening of a ... Nagamura, Associate Partner, Red Nucleus R&D. , Red Nucleus announced the new office ...
Breaking Biology Technology:
Cached News: